Major Depressive Disorder (MDD)

SEP 9, 2026 · INTERVENTIONAL STUDY

Evaluating Conversational Artificial Intelligence for Depression Management

ClinicalTrials.gov

This is a study registration with no posted results; it describes a planned interventional trial in major depressive disorder using a surrogate endpoint (perceptions of empathy) in a small, single-centre cohort with within-subject design.

SEP 8, 2026 · PHASE 3 TRIAL

Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant Monotherapy

ClinicalTrials.gov

This is a Phase 3 trial registration with no results reported; the study is not yet recruiting, so evidence on efficacy and safety cannot be assessed.

SEP 4, 2026 · PHASE EARLY PHASE 1 TRIAL

Individualized fMRI-guided TMS for Depression

ClinicalTrials.gov

This is an early-phase (Phase 1) interventional trial registration with no posted results; it describes a planned mechanistic study of fMRI-guided TMS targeting a specific brain circuit in depression.

SEP 4, 2026 · INTERVENTIONAL STUDY

Comparison of Efficacy of Minocyclin and Celecoxib as Adjunctive Treatment in Treatment Resistant Cases of Major Depressive Disorder

ClinicalTrials.gov

This is a completed registry record reporting a planned RCT design and enrollment, but no results are posted; outcome data cannot be assessed.

SEP 3, 2026 · PHASE 2/3 TRIAL

Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression

ClinicalTrials.gov

This is a Phase 2/3 trial registration with no posted results; it describes a planned intervention combining ketamine and behavioral activation for treatment-resistant depression but carries no efficacy or safety data.

AUG 19, 2026 · INTERVENTIONAL STUDY

Imaging- vs. Scalp-Targeted Accelerated TMS for Depression: The Number Needed to Scan Trial

ClinicalTrials.gov

This is a clinical trial registry record with no posted results; the study is not yet recruiting and describes only the planned design and rationale.

AUG 17, 2026 · PHASE 2 TRIAL

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

ClinicalTrials.gov

This is a Phase 2 trial registration with no reported results; the study is actively recruiting and outcome data are not yet available.

AUG 17, 2026 · PHASE 2 TRIAL

An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

ClinicalTrials.gov

This is a Phase 2 open-label extension study with no results posted; it is designed to assess safety and tolerability in a planned 360-participant cohort, typical of early-phase investigation.